Kenneth T. Mills, President and CEO at REGENXBIO Inc. (RGNX), sold 30,000 shares at $16.88 ($503K) on 2024-02-14, disclosed to the SEC on 2024-02-16.
Scheduled sale ($503k) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.47 | 4,652 | $77K | 15.2% |
| 2 | $16.47 | 4,652 | $77K | 15.2% |
| 3 | $16.88 | 10,348 | $175K | 34.8% |
| 4 | $16.88 | 10,348 | $175K | 34.8% |
| Total | $16.75 avg | 30,000 | $503K | 100% |
| Filing → |
| RGNX | SELL | 2024-07-18 | $33K | — | Filing → |
| RGNX | SELL | 2024-05-16 | $237K | — | Filing → |
| RGNX | SELL | 2024-04-17 | $273K | — | Filing → |